Hannah K Weir1, Christopher J Johnson, Trevor D Thompson. 1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy. MS-K55, Atlanta, GA 30341, USA. hbw4@cdc.gov
Abstract
PURPOSE: Different rules for registering multiple primary (MP) cancers are used by cancer registries throughout the world, making international data comparisons difficult. This study evaluates the effect of Surveillance, Epidemiology, and End Results (SEER) and International Association of Cancer Registries (IACR) MP rules on population-based cancer survival estimates. METHODS: Data from five US states and six metropolitan area cancer registries participating in the SEER Program were used to estimate age-standardized relative survival (RS%) for first cancers-only and all first cancers matching the selection criteria according to SEER and IACR MP rules for all cancer sites combined and for the top 25 cancer site groups among men and women. RESULTS: During 1995-2008, the percentage of MP cancers (all sites, both sexes) increased 25.4 % by using SEER rules (from 14.6 to 18.4 %) and 20.1 % by using IACR rules (from 13.2 to 15.8 %). More MP cancers were registered among females than among males, and SEER rules registered more MP cancers than IACR rules (15.8 vs. 14.4 % among males; 17.2 vs. 14.5 % among females). The top 3 cancer sites with the largest differences were melanoma (5.8 %), urinary bladder (3.5 %), and kidney and renal pelvis (2.9 %) among males, and breast (5.9 %), melanoma (3.9 %), and urinary bladder (3.4 %) among females. Five-year survival estimates (all sites combined) restricted to first primary cancers-only were higher than estimates by using first site-specific primaries (SEER or IACR rules), and for 11 of 21 sites among males and 11 of 23 sites among females. SEER estimates are comparable to IACR estimates for all site-specific cancers and marginally higher for all sites combined among females (RS 62.28 vs. 61.96 %). CONCLUSION: Survival after diagnosis has improved for many leading cancers. However, cancer patients remain at risk of subsequent cancers. Survival estimates based on first cancers-only exclude a large and increasing number of MP cancers. To produce clinically and epidemiologically relevant and less biased cancer survival estimates, data on all cancers should be included in the analysis. The multiple primary rules (SEER or IACR) used to identify primary cancers do not affect survival estimates if all first cancers matching the selection criteria are used to produce site-specific survival estimates.
PURPOSE: Different rules for registering multiple primary (MP) cancers are used by cancer registries throughout the world, making international data comparisons difficult. This study evaluates the effect of Surveillance, Epidemiology, and End Results (SEER) and International Association of Cancer Registries (IACR) MP rules on population-based cancer survival estimates. METHODS: Data from five US states and six metropolitan area cancer registries participating in the SEER Program were used to estimate age-standardized relative survival (RS%) for first cancers-only and all first cancers matching the selection criteria according to SEER and IACR MP rules for all cancer sites combined and for the top 25 cancer site groups among men and women. RESULTS: During 1995-2008, the percentage of MP cancers (all sites, both sexes) increased 25.4 % by using SEER rules (from 14.6 to 18.4 %) and 20.1 % by using IACR rules (from 13.2 to 15.8 %). More MP cancers were registered among females than among males, and SEER rules registered more MP cancers than IACR rules (15.8 vs. 14.4 % among males; 17.2 vs. 14.5 % among females). The top 3 cancer sites with the largest differences were melanoma (5.8 %), urinary bladder (3.5 %), and kidney and renal pelvis (2.9 %) among males, and breast (5.9 %), melanoma (3.9 %), and urinary bladder (3.4 %) among females. Five-year survival estimates (all sites combined) restricted to first primary cancers-only were higher than estimates by using first site-specific primaries (SEER or IACR rules), and for 11 of 21 sites among males and 11 of 23 sites among females. SEER estimates are comparable to IACR estimates for all site-specific cancers and marginally higher for all sites combined among females (RS 62.28 vs. 61.96 %). CONCLUSION: Survival after diagnosis has improved for many leading cancers. However, cancerpatients remain at risk of subsequent cancers. Survival estimates based on first cancers-only exclude a large and increasing number of MP cancers. To produce clinically and epidemiologically relevant and less biased cancer survival estimates, data on all cancers should be included in the analysis. The multiple primary rules (SEER or IACR) used to identify primary cancers do not affect survival estimates if all first cancers matching the selection criteria are used to produce site-specific survival estimates.
Authors: Bernard Rachet; Camille Maringe; Ula Nur; Manuela Quaresma; Anjali Shah; Laura M Woods; Libby Ellis; Sarah Walters; David Forman; John Steward; Michel P Coleman Journal: Lancet Oncol Date: 2009-03-19 Impact factor: 41.316
Authors: M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards Journal: Lancet Date: 2010-12-21 Impact factor: 79.321
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Hannah K Weir; Christopher J Johnson; Angela B Mariotto; Donna Turner; Reda J Wilson; Diane Nishri; Kevin C Ward Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Ying L Liu; Karen A Cadoo; Semanti Mukherjee; Aliya Khurram; Kaitlyn Tkachuk; Yelena Kemel; Anna Maio; Sami Belhadj; Maria I Carlo; Alicia Latham; Michael F Walsh; Marianne E Dubard-Gault; Yuhan Wang; A Rose Brannon; Erin Salo-Mullen; Margaret Sheehan; Elise Fiala; Bryan Devolder; Sita Dandiker; Diana Mandelker; Ahmet Zehir; Marc Ladanyi; Michael F Berger; David B Solit; Chaitanya Bandlamudi; Vignesh Ravichandran; Dean F Bajorin; Zsofia K Stadler; Mark E Robson; Joseph Vijai; Venkatraman Seshan; Kenneth Offit Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-22 Impact factor: 4.090
Authors: Sandi L Pruitt; Hong Zhu; Daniel F Heitjan; Asal Rahimi; Bhumika Maddineni; Anna Tavakkoli; Ethan A Halm; David E Gerber; Danyi Xiong; Caitlin C Murphy Journal: Breast Cancer Res Treat Date: 2021-02-23 Impact factor: 4.872
Authors: Sandi L Pruitt; David E Gerber; Hong Zhu; Daniel F Heitjan; Bhumika Maddineni; Danyi Xiong; Amit G Singal; Anna Tavakkoli; Ethan A Halm; Caitlin C Murphy Journal: Cancer Med Date: 2021-06-30 Impact factor: 4.452